US Food and Drug Administration Commissioner Marty Makary said he’s trying to persuade Vinay Prasad, the agency’s former head ...

The gene therapy chief wanted to block fast-track drug approvals.

Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...

The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office ...

Vinay Prasad, a top official at the Food and Drug Administration, has suddenly departed after a series of controversial ...

7月29日，美卫生部发言人宣布FDA生物制品评价与研究中心（CBER）主任Vinay Prasad离职，距离其上任不过百日。上一任CBER主任Peter Marks于3月28日被迫离职。

U.S. Food and Drug Administration officials should encourage the thoughtful and careful evaluation of drugs.

目前来看，市场的担忧并非空穴来风。Replimune的遭遇更是给所有创新药企敲响了警钟，在FDA领导层更迭的背景下，监管标准的连贯性正在断裂，曾经达成共识的临床设计，也可能在新主任上任后面临颠覆性质疑。

Dr. Vinay Prasad, the chief scientific officer at the Food and Drug Administration, has resigned after only three months in ...

Vinay Prasad is leaving Sensible Medicine to take a senior role at the US FDA. He has our enthusiastic support. Prasad is ...

Vinay Prasad recently drew outrage from conservatives, including Laura Loomer, who disagreed with his approach to approving ...